热搜词：
注册
登录
CN
  • CN
  • EN

产品中心 抗体 配对抗体

所有图片（1/1）

SV2A Recombinant Rabbit mAb (SDT-3732-77)

Synaptic vesicle glycoprotein 2A,KIAA0736,SV2A

价格 询价 请咨询客服
货号 S0B3742
规格
数量
收藏 分享
产品介绍

产品介绍 评论(0)

产品规格

  • 宿主来源

    Rabbit

  • 抗原名称

    SV2A

  • 分子别名

    Synaptic vesicle glycoprotein 2A; KIAA0736; SV2A

  • 免疫原

    Recombinant Protein

  • Accession

    Q7L0J3

  • 克隆号

    SDT-3732-77

  • 抗体类型

    Recombinant mAb

  • 抗体同种型

    IgG

  • 反应种属 ?

    Hu, Ms

  • 预测反应种属
    (反应种属缩写表)

    Rt

  • 交叉反应

    No cross-reactivity against UCH-L1

  • 纯化方式

    Protein A

  • 浓度

    2 mg/ml

  • 标记

    Unconjugated

  • 性状

    Liquid

  • 缓冲体系

    PBS pH7.4, 0.03% Proclin 300

  • 储存条件

    12 months from date of receipt, 2 to 8 °C as supplied

  • 应用

    Sandwich ELISA

    CLIA

背景介绍

  • SV2A, a synaptic vesicle glycoprotein, serves as a promising synaptic density biomarker for Alzheimer’s disease (AD) diagnosis. In AD, SV2A levels in cerebrospinal fluid (CSF), serum, and brain tissue decline significantly, correlating with cognitive impairment and disease progression. SV2A PET enables in vivo synaptic loss visualization, offering early detection of AD-related brain dysfunction before obvious atrophy. CSF/serum SV2A strongly correlates with PET results, providing minimally invasive alternatives for synaptic assessment.

    Notably, serum SV2A shows high sensitivity (97.8%) for identifying amnestic mild cognitive impairment (aMCI), outperforming NfL, GFAP, and p-tau217 in early AD detection. It also effectively distinguishes high-risk individuals from cognitively unimpaired populations.

    As a key synaptic integrity marker, SV2A aids early diagnosis, progression monitoring, and risk stratification in AD, complementing existing pathological biomarkers.

  • 配对推荐

评论(0)